| 1 | 32167180 | The establishment of reference sequence for SARS-CoV-2 and variation analysis. | J Med Virol | 2020 Jun |
1 |
| 2 | 32201080 | Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. | Biochem Biophys Res Commun | 2020 May 21 |
1 |
| 3 | 32225175 | Structural basis of receptor recognition by SARS-CoV-2. | Nature | 2020 May |
1 |
| 4 | 32245784 | A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. | Science | 2020 May 8 |
2 |
| 5 | 32293168 | Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. | ACS Nano | 2020 Apr 28 |
2 |
| 6 | 32335456 | The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? | Med Hypotheses | 2020 Sep |
1 |
| 7 | 32345140 | Stilbene-based natural compounds as promising drug candidates against COVID-19. | J Biomol Struct Dyn | 2021 Jun |
5 |
| 8 | 32362314 | A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. | Mol Cell | 2020 May 21 |
1 |
| 9 | 32363391 | Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. | Glycobiology | 2020 Dec 9 |
7 |
| 10 | 32366695 | Site-specific glycan analysis of the SARS-CoV-2 spike. | Science | 2020 Jul 17 |
2 |
| 11 | 32374903 | SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. | Int J Clin Pract | 2020 Aug |
2 |
| 12 | 32404436 | TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. | Sci Immunol | 2020 May 13 |
1 |
| 13 | 32404529 | Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. | J Virol | 2020 Jul 16 |
1 |
| 14 | 32405156 | Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. | Int J Antimicrob Agents | 2020 Aug |
1 |
| 15 | 32475223 | Antiviral effects of probiotic metabolites on COVID-19. | J Biomol Struct Dyn | 2021 Jul |
5 |
| 16 | 32485251 | A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2. | Int J Biol Macromol | 2020 Oct 1 |
1 |
| 17 | 32518941 | Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics. | Glycobiology | 2021 Jan 9 |
2 |
| 18 | 32532094 | The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. | Viruses | 2020 Jun 10 |
2 |
| 19 | 32545268 | Potential of Flavonoid-Inspired Phytomedicines against COVID-19. | Molecules | 2020 Jun 11 |
1 |
| 20 | 32551648 | The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach. | J Proteome Res | 2020 Nov 6 |
1 |
| 21 | 32562764 | Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection. | Environ Toxicol Pharmacol | 2020 Oct |
5 |
| 22 | 32579907 | Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. | Int J Infect Dis | 2020 Sep |
3 |
| 23 | 32587973 | The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. | bioRxiv | 2020 Jun 12 |
4 |
| 24 | 32589459 | Ocular Surface Expression of SARS-CoV-2 Receptors. | Ocul Immunol Inflamm | 2020 Jul 3 |
1 |
| 25 | 32593613 | Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. | Biochem Pharmacol | 2020 Aug |
1 |
| 26 | 32605194 | Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. | Pathogens | 2020 Jun 28 |
1 |
| 27 | 32637953 | A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies. | bioRxiv | 2020 Jun 30 |
1 |
| 28 | 32638018 | Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. | Cardiovasc Res | 2020 Aug 1 |
1 |
| 29 | 32654533 | Design of engineered surfaces for prospective detection of SARS-CoV-2 using quartz crystal microbalance-based techniques. | Expert Rev Proteomics | 2020 Jun |
1 |
| 30 | 32656452 | Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor. | ACS Omega | 2020 Jul 7 |
5 |
| 31 | 32672061 | Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. | Future Med Chem | 2020 Sep |
4 |
| 32 | 32681121 | ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. | Eur J Hum Genet | 2020 Nov |
1 |
| 33 | 32696720 | Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19. | J Biomol Struct Dyn | 2021 Oct |
7 |
| 34 | 32698689 | Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an <i>in silico</i> study for drug development. | J Biomol Struct Dyn | 2021 Oct |
2 |
| 35 | 32699853 | SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. | bioRxiv | 2020 Jul 14 |
12 |
| 36 | 32703906 | Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. | Science | 2020 Sep 18 |
1 |
| 37 | 32729392 | Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19. | J Biomol Struct Dyn | 2021 Oct |
3 |
| 38 | 32736596 | ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. | Trials | 2020 Jul 31 |
2 |
| 39 | 32737467 | A thermostable, closed SARS-CoV-2 spike protein trimer. | Nat Struct Mol Biol | 2020 Oct |
3 |
| 40 | 32741259 | Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. | J Biomol Struct Dyn | 2020 Aug 3 |
2 |
| 41 | 32743575 | Simulations support the interaction of the SARS-CoV-2 spike protein with nicotinic acetylcholine receptors. | bioRxiv | 2020 Sep 14 |
1 |
| 42 | 32746720 | Deciphering the protein motion of S1 subunit in SARS-CoV-2 spike glycoprotein through integrated computational methods. | J Biomol Struct Dyn | 2021 Oct |
1 |
| 43 | 32753553 | Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. | Science | 2020 Sep 4 |
1 |
| 44 | 32757981 | <i>In silico</i> Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. | OMICS | 2020 Oct |
2 |
| 45 | 32762417 | Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. | J Biomol Struct Dyn | 2021 Nov |
1 |
| 46 | 32768503 | In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. | Eur J Pharmacol | 2020 Nov 5 |
2 |
| 47 | 32770567 | Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. | Drug Dev Res | 2021 Feb |
9 |
| 48 | 32772313 | Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19. | Nat Prod Bioprospect | 2020 Oct |
3 |
| 49 | 32793181 | Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An <i>in silico</i> Analysis. | Front Microbiol | 2020 |
2 |
| 50 | 32793901 | Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. | bioRxiv | 2020 Aug 6 |
1 |